Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317741 · ClinicalTrials.gov registry record · Phase 1
SAD Study of IA-14069
A Phase 1 study, sponsored by ILAb Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT05317741 is a Phase 1 study that has completed, run by ILAb Co.. The registered enrollment target is 40 participants.
The verdict
NCT05317741, a Phase 1 study, has completed, sponsored by ILAb Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, food effect, and pharmacodynamics following a single oral dose of IA-14069 in healthy male subjects.
Interventions
- DRUG Placebo
- DRUG IA-14069
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2022-09-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05317741
The ClinicalTrials.gov registry entry for NCT05317741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ILAb Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05317741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05317741 about?
NCT05317741 is a clinical study titled "SAD Study of IA-14069". The purpose of this study is to assess the safety, tolerability, pharmacokinetics, food effect, and pharmacodynamics following a single oral dose of IA-14069 in healthy male subjects.
What is the current status of trial NCT05317741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-08-23. Estimated completion is 2022-09-08.
What interventions are being tested in trial NCT05317741?
The interventions under investigation include: Placebo (DRUG), IA-14069 (DRUG).
Who is sponsoring clinical trial NCT05317741?
This trial is sponsored by ILAb Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.